Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.93
+0.57 (7.74%)
At close: Aug 7, 2026, 4:00 PM EDT
7.95
+0.02 (0.25%)
Pre-market: Aug 10, 2026, 7:45 AM EDT
Xeris Biopharma Holdings Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 121.75 | 111.04 | 71.62 | 67.45 | 121.97 | 67.27 |
Short-Term Investments | - | - | - | 5 | - | 35.16 |
Cash & Short-Term Investments | 121.75 | 111.04 | 71.62 | 72.45 | 121.97 | 102.43 |
Cash Growth | 105.36% | 55.04% | -1.15% | -40.60% | 19.07% | -23.44% |
Accounts Receivable | 58.11 | 51.05 | 40.42 | 39.2 | 30.83 | 17.46 |
Inventory | 80.93 | 68.67 | 48.18 | 38.84 | 24.74 | 18.12 |
Other Current Assets | 13.98 | 9.55 | 7.45 | 5.78 | 9.29 | 4.59 |
Total Current Assets | 274.76 | 240.31 | 167.66 | 156.26 | 186.82 | 142.6 |
Net Property, Plant & Equipment | 26.61 | 27.06 | 28.21 | 29.18 | 9.51 | 6.63 |
Other Intangible Assets | 82.66 | 88.08 | 98.92 | 109.76 | 120.61 | 131.45 |
Goodwill | 22.86 | 22.86 | 22.86 | 22.86 | 22.86 | 22.86 |
Other Long-Term Assets | 5.03 | 5.22 | 5.41 | 4.54 | 4.73 | 0.83 |
Total Assets | 411.91 | 383.53 | 323.06 | 322.6 | 344.52 | 304.36 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 9.34 | 3.08 | 2.29 | 11.57 | 4.61 | 8.92 |
Accrued Expenses | 105.16 | 95.38 | 75.88 | 36.35 | 64.78 | 68.13 |
Current Portion of Long-Term Debt | 63.78 | - | 15.1 | - | - | - |
Current Portion of Leases | 6.31 | 6.23 | 6.08 | 3.5 | 1.58 | - |
Other Current Liabilities | 4.98 | 4.89 | 1.09 | 20.28 | 2.66 | 1.99 |
Total Current Liabilities | 189.57 | 109.57 | 100.44 | 95.19 | 73.62 | 79.04 |
Long-Term Debt | 188.81 | 220.34 | 217.01 | 190.93 | 187.08 | 88.07 |
Long-Term Leases | 30.54 | 31.53 | 33.26 | 34.76 | 9.4 | - |
Other Long-Term Liabilities | 12.72 | 8.4 | 1.97 | 8.5 | 29.24 | 42.02 |
Total Long-Term Liabilities | 232.07 | 260.26 | 252.23 | 234.19 | 225.71 | 130.09 |
Total Liabilities | 421.64 | 369.84 | 352.68 | 329.38 | 299.34 | 209.13 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 690.43 | 685 | 642.26 | 610.25 | 599.97 | 555.36 |
Accumulated Other Comprehensive Income | -0.01 | -0.03 | -0.03 | -0.03 | -0.02 | -0.03 |
Retained Earnings | -700.17 | -671.31 | -671.86 | -617.03 | -554.77 | -460.11 |
Shareholders' Equity | -9.73 | 13.69 | -29.62 | -6.78 | 45.19 | 95.23 |
Total Liabilities & Equity | 411.91 | 383.53 | 323.06 | 322.6 | 344.52 | 304.36 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 289.44 | 258.1 | 271.45 | 229.19 | 198.06 | 88.07 |
Net Cash (Debt) | -167.7 | -147.06 | -199.83 | -156.74 | -76.09 | 14.37 |
Net Cash Growth | - | - | - | - | - | -69.28% |
Net Cash Per Share | -0.95 | -0.85 | -1.36 | -1.14 | -0.56 | 0.18 |
Book Value | -9.73 | 13.69 | -29.62 | -6.78 | 45.19 | 95.23 |
Book Value Per Share | -0.05 | 0.08 | -0.20 | -0.05 | 0.33 | 1.21 |
Tangible Book Value | -115.25 | -97.25 | -151.4 | -139.41 | -98.28 | -59.08 |
Tangible Book Value Per Share | -0.65 | -0.56 | -1.03 | -1.01 | -0.72 | -0.75 |